首站-论文投稿智能助手
典型文献
Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy
文献摘要:
Parkin,an E3 ubiquitin ligase,plays a role in maintaining mitochondrial homeostasis through targeting damaged mitochondria for mitophagy.Accumulating evidence suggests that the acetylation modification of the key mitophagy machinery influences mitophagy level,but the underlying mechanism is poorly understood.Here,our study demonstrated that inhibition of histone deacetylase(HDAC)by treatment of HDACis activates mitophagy through mediating Parkin acetylation,leading to inhibition of cervical cancer cell proliferation.Bioinformatics analysis shows that Parkin expression is inversely correlated with HDAC2 expression in human cervical cancer,indicating the low acetylation level of Par-kin.Using mass spectrometry,Parkin is identified to interact with two upstream molecules,acetylase acetyl-CoA acetyltransferase 1(ACAT1)and deacetylase HDAC2.Under treatment of suberoylanilide hydroxamic acid(SAHA),Parkin is acetylated at lysine residues 129,220 and 349,located in different domains of Parkin protein.In in vitro experiments,combined mutation of Parkin largely attenuate the interaction of Parkin with PTEN induced putative kinase 1(PINK1)and the function of Parkin in mito-phagy induction and tumor suppression.In tumor xenografts,the expression of mutant Parkin impairs the tumor suppressive effect of Parkin and decreases the anticancer activity of SAHA.Our results reveal an acetylation-dependent regulatory mechanism governing Parkin in mitophagy and cervical carcinogenesis,which offers a new mitophagy modulation strategy for cancer therapy.
文献关键词:
作者姓名:
Xin Sun;Yuhan Shu;Guiqin Ye;Caixia Wu;Mengting Xu;Ruilan Gao;Dongsheng Huang;Jianbin Zhang
作者机构:
Department of Oncology,Cancer Center of Zhejiang Provincial People's Hospital,Affiliated People's Hospital,Hangzhou Medical College,Hangzhou 310014,China;College of Biomedical Engineering&Instrument Science,Zhejiang University,Hangzhou 310028,China;Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province,Hangzhou Medical College,Hangzhou 310014,China;Clinical Research Institute,Zhejiang Provincial People,s Hospital,Affiliated People,s Hospital,Hangzhou Medical College,Hangzhou 310014,China;Department of Hematology,the First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310006,China
引用格式:
[1]Xin Sun;Yuhan Shu;Guiqin Ye;Caixia Wu;Mengting Xu;Ruilan Gao;Dongsheng Huang;Jianbin Zhang-.Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy)[J].药学学报(英文版),2022(02):838-852
A类:
acetylase,suberoylanilide
B类:
Histone,deacetylase,inhibitors,cervical,growth,through,Parkin,acetylation,mediated,mitophagy,E3,ubiquitin,ligase,plays,role,maintaining,mitochondrial,homeostasis,targeting,damaged,Accumulating,evidence,suggests,that,modification,key,machinery,influences,level,but,underlying,mechanism,poorly,understood,Here,our,study,demonstrated,inhibition,histone,by,treatment,HDACis,activates,mediating,leading,cell,proliferation,Bioinformatics,analysis,shows,expression,inversely,correlated,HDAC2,human,indicating,low,Using,mass,spectrometry,identified,two,upstream,molecules,CoA,acetyltransferase,ACAT1,Under,hydroxamic,acid,SAHA,acetylated,lysine,residues,located,different,domains,protein,In,vitro,experiments,combined,mutation,largely,attenuate,interaction,PTEN,induced,putative,kinase,PINK1,function,induction,tumor,suppression,xenografts,mutant,impairs,suppressive,effect,decreases,anticancer,activity,Our,results,reveal,dependent,regulatory,governing,carcinogenesis,which,offers,new,modulation,strategy,therapy
AB值:
0.570072
相似文献
Romidepsin (FK228) improves the survival of allogeneic skin grafts through downregulating the production of donor-specific antibody via suppressing the IRE1 α-XBP1 pathway
Yuliang GUO;Siyu SONG;Xiaoxiao DU;Li TIAN;Man ZHANG;Hongmin ZHOU;Zhonghua Klaus CHEN;Sheng CHANG-Institute of Organ Transplantation,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China;Key Laboratory of Organ Transplantation,Ministry of Education,NHC Key Laboratory of Organ Transplantation,Key Laboratory of Organ Transplantation,Chinese Academy of Medical Sciences,Wuhan 430030,China;Henan Key Laboratory of Digestive Organ Transplantation,Open and Key Laboratory of Hepatobiliary&Pancreatic Surgery and Digestive Organ Transplantation at Henan Universities,Zhengzhou Key Laboratory of Hepatobiliary&Pancreatic Diseases and Organ Transplantation,Department of Hepatobiliary and Pancreatic Surgery,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Cardiothoracic and Vascular Surgery,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China
N6?methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance
Xian Lin;Feng Wang;Jian Chen;Jing Liu;Yi?Bin Lin;Li Li;Chuan?Ben Chen;Qin Xu-Departments of Gynecology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Department of Radiation Oncology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Shenzhen Key Laboratory of Immunity and Inflammatory Diseases,Peking University Shenzhen Hospital,Shenzhen Peking University?the Hong Kong University of Science and Technology Medical Center,Shenzhen 518036,Guangdong,China;Outpatient Department,Fujian Hospital of People's Armed Police,Fujian Medical University,Fuzhou 350014,China
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
Leyi Yao;Qian Zhao;Ding Yan;Ziying Lei;Yali Hao;Jinghong Chen;Qian Xue;Xiaofen Li;Qingtian Huang;Daolin Tang;Q.Ping Dou;Xin Chen;Jinbao Liu-Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,State Key Laboratory of Respiratory Disease,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;Institute of Digestive Disease of Guangzhou Medical University,The Sixth Affiliated Hospital of Guangzhou Medical University,Qingyuan People's Hospital,Qingyuan 511518,China;School of Public Health,Guangzhou Medical University,Guangzhou,511436,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
P300/CBP inhibition sensitizes mantle cell lymphoma to PI3Kδ inhibitor idelalisib
Xiao-ru Zhou;Xiao Li;Li-ping Liao;Jie Han;Jing Huang;Jia-cheng Li;Hong-ru Tao;Shi-jie Fan;Zhi-feng Chen;Qi Li;Shi-jie Chen;Hong Ding;Ya-xi Yang;Bing Zhou;Hua-liang Jiang;Kai-xian Chen;Yuan-yuan Zhang;Chuan-xin Huang;Cheng Luo-Drug Discovery and Design Center,The Center for Chemical Biology,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;School of Life Science and Technology,ShanghaiTech University,Shanghai 200031,China;Department of Medicinal Chemistry,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Shanghai Institute of Immunology and Department of Immunology and Microbiology,Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education,Faculty of Basic Medicine,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Kanglexin delays heart aging by promoting mitophagy
Hui-min Li;Xin Liu;Zi-yu Meng;Lei Wang;Li-min Zhao;Hui Chen;Zhi-xia Wang;Hao Cui;Xue-qing Tang;Xiao-han Li;Wei-na Han;Xue Bai;Yuan Lin;Heng Liu;Yong Zhang;Bao-feng Yang-Department of Pharmacology(the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China,Key Laboratory of Cardiovascular Research,Ministry of Education),College of Pharmacy,Harbin Medical University,Harbin 150081,China;Department of Medicinal Chemistry and Natural Medicine Chemistry,College of Pharmacy,Harbin Medical University,Harbin 150081,China;Research Unit of Noninfectious Chronic Diseases in Frigid Zone,Chinese Academy of Medical Sciences,Harbin 150086,China;Institute of Metabolic Disease,Heilongjiang Academy of Medical Science,Harbin 150086,China;Department of Pharmacology and Therapeutics,Melbourne School of Biomedical Sciences,Faculty of Medicine,Dentistry and Health Sciences University of Melbourne,Melbourne,Australia
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。